Future research and clinical trials are necessary to better define the safety, efficacy, and specific applications of GLUT1-targeted therapies, ensuring they fit seamlessly into the multidisciplinary framework essential for managing GDM and optimizing fetal outcomes. This evidence concerns the gene SLC2A1 and gestational diabetes.